Table 3.
Summary of 67 published reports on COVID-19 vaccine-related lymphadenopathy.*
| Type of vaccine | Number of cases |
|---|---|
| Pfizer-BioNTech (BNT 162b2) mRNA COVID-19 vaccine | 2859 |
| Moderna (mRNA-1273) COVID-19 vaccine | 103 |
| Oxford/AstraZeneca (AZD1222) adenovirus vector COVID-19 vaccine | 12 |
| mRNA vaccine without specification⁎⁎⁎ | 8 |
| COVID-19 vaccine without specification† | 88 |
| Johnson & Johnson's Janssen COVID-19 vaccine | 1 |
| Gam-COVID-Vac (Sputnik V) vaccine | 1 |
| Location of lymphadenopathy | Number of cases |
| Axillary only | 2319 |
| Supraclavicular and/or infraclavicular only | 44 |
| Cervical area only | 25 |
| Axillary and peri-clavicular‡ area together | 12 |
| Axillary and cervical area together | 1 |
| Axillary, peri-clavicular‡ and cervical area together | 3 |
| Axillary and pectoral area together | 3 |
| Systemic§ | 4 |
| Specific location not provided in the article¶ | 660 |
| Ipsilateral inguinal and iliac lymphadenopathy after injection on thigh muscle‖ | 1 |
| Total number of cases | 3072†† |
Only articles with clear demonstration of the cases and full-text accessibility were included between January 1 and October 1, 2021** Number of cases described as COVID-19-related lymphadenopathy in the article, not total number or enrolled number of the study in each literature.
Cases from articles describing the vaccine only as ‘mRNA COVID-19 vaccine’ without specification.
Cases from articles describing the vaccine only as ‘COVID-19 vaccine’ without specification.
Including supraclavicular, infraclavicular and sub-clavicular area as mentioned in the articles.
Cases showing contralateral axillary lymphadenopathy or any other area of the body except ipsilateral axilla, peri-clavicular and cervical area to vaccine injection site [65,71,94].
Cases from one article describing lymphadenopathy only as ‘lymphadenopathy’ without anatomical location [43].
Considered as local reaction given the case had COVID-19 vaccine injection on thigh muscle instead of usual deltoid muscle [44].
All the cases without clear number and corresponding localization of the lymphadenopathy were excluded from this summary table.